Trilipix

Fenofibrate

Method of action: Hypocholesterolemic, Lipid Modifying Agents, Lipid-Lowering

Treatment option: Heart Disease, Hyperlipoproteinemia, Hypertriglyceridemia, Hypercholesterolemia, Dyslipidemia, Coronary Heart Disease, Smoking, Pancreatitis, Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trilipix

Property	Description
Active ingredient	Fenofibric acid (as Choline fenofibrate)
Form	Delayed-release capsule
Pharmacological class	Fibric Acid Derivative (Fibrate)
Common use	Modifying blood lipid levels (antilipemic agent)
Origin	Synthetic

Trilipix is a type of prescription medicine (Rx) that functions as a powerful lipid-modifying agent used to help manage abnormal fat levels in the bloodstream. It belongs to the Fibric Acid Derivative class, also known as a Fibrate, which is a specific type of therapeutic agent designed to correct imbalances in blood lipids. This product is a single-ingredient product used as an adjunctive therapy for adults, clinically recognized for its action on circulating triglycerides.

What Type of Medicine is Trilipix? (Classification and Identity)

Trilipix is classified as a Fibric Acid Derivative, a distinct pharmacological class of agents that target blood fats differently from other common cholesterol drugs. This classification is based on the drug's core chemical structure. Its differentiating factor lies in its active component, fenofibric acid, which acts as a Peroxisome Proliferator-Activated Receptor alpha (PPAR α) agonist. This specific mechanism is recognized for its role in regulating genes related to fat metabolism.

What is the Composition and Form of Trilipix? (Substance and Delivery)

The therapeutic effect is derived from the active ingredient, fenofibric acid, which is contained within the drug as choline fenofibrate. This compound is a pro-drug, meaning the administered choline fenofibrate must be converted by the body into the active fenofibric acid in vivo to exert its effect. Trilipix is uniquely supplied as a delayed-release capsule, an oral solid formulation designed for absorption via the oral route. This specific pharmaceutical form is a key differentiating feature, as its design is intended to optimize the bioavailability of the fenofibric acid component.

What is the General Purpose of Fenofibric Acid? (High-Level Benefit)

The general purpose of this medicine is to help normalize blood lipid levels by reducing excessive amounts of certain circulating fats, particularly triglycerides. The fenofibric acid mechanism accelerates the lipolysis (breakdown) and removal of these high-energy fats from the bloodstream. A typical use scenario involves its application for patients requiring significant reduction in high triglyceride levels. By selectively targeting these lipid-processing pathways, the medicine offers a therapeutic benefit in managing conditions defined by abnormal blood fat profiles.

What side effects are possible with Trilipix ?

Possible Side Effects and Safety Information

The following safety information for Trilipix (fenofibric acid) is derived strictly from government regulatory documentation, such as the U.S. Food and Drug Administration (FDA) Prescribing Information, and details the officially documented adverse reactions and safety constraints.

Documented Adverse Reactions

The most commonly documented adverse reactions observed in clinical trials, classified as Common (incidence ge 2% and greater than placebo), fall into several system-organ classes:

System Organ Class (SOC)	Common Adverse Reactions
Investigations	Abnormal liver tests ( ALT/ AST increase), CPK increased
Infections & Infestations	Upper Respiratory Tract Infection, Nasopharyngitis
Musculoskeletal	Back Pain, Myalgia (Muscle Pain), Arthralgia (Joint Pain)
Gastrointestinal	Nausea, Diarrhea, Dyspepsia
Nervous System	Headache, Dizziness

Serious Safety Concerns and Contraindications

The FDA label highlights several serious adverse reactions, including: Hepatotoxicity (severe liver injury), Myopathy and Rhabdomyolysis (serious muscle conditions), Pancreatitis, Cholelithiasis (gallstones), and Hypersensitivity Reactions (e.g., Anaphylaxis, SCARs).

Trilipix is Contraindicated in specific patient populations due to safety risks. This includes individuals with severe renal impairment, active liver disease, or pre-existing gallbladder disease. It is also contraindicated for use in nursing mothers.

Safety-Related Restrictions and Monitoring

Official labeling requires periodic monitoring of both liver function tests ( ALT/ AST) and renal function throughout the course of treatment. Caution is advised when the medicine is used with oral coumarin anticoagulants (e.g., warfarin), as this combination may increase the risk of bleeding and necessitate careful adjustment of the anticoagulant.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Trilipix (fenofibric acid) overdose is primarily structured around required management procedures rather than specific clinical manifestations. The official regulatory labeling does not document specific symptoms or clinical signs that are known to result from an overdose of this medication.

Emergency Actions Required and Monitoring

For any suspected overdose of fenofibric acid, general supportive care of the patient is formally indicated as the mandated action. Immediate medical attention should be sought for any suspected overdose to ensure that appropriate emergency procedures are initiated. The required supportive care includes essential clinical actions such as the continuous monitoring of vital signs and careful observation of clinical status.

Management Procedures and Limitations

In the event of an overdose, management procedures are directed toward the elimination of unabsorbed drug from the system, if clinically indicated. These specific regulatory-documented measures may include procedures such as emesis (induced vomiting) or gastric lavage (stomach pumping). During the application of these interventions, observing usual precautions to maintain the airway is officially required. Because fenofibric acid is highly bound to plasma proteins, official regulatory guidance states explicitly that hemodialysis should not be considered as an effective measure for treatment. No specific antidote is mentioned in the regulatory labeling.

Therapeutic Uses of Trilipix

Main Uses of Trilipix

Trilipix is a prescription medication used to manage specific lipid (fat) levels in the blood. It belongs to a class of drugs known as fibrates, which work by altering the way the liver processes and distributes lipids. The primary applications for this medication include:

Treatment of Severe Hypertriglyceridemia

Trilipix is used to reduce very high levels of triglycerides in the blood. Elevated triglycerides can increase the risk of inflammation of the pancreas (pancreatitis). When diet and lifestyle changes alone are insufficient, this medication helps lower these fat levels to a more manageable range.

Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemia

In cases where individuals have high levels of "bad" cholesterol (low-density lipoprotein or LDL) or a combination of high LDL and high triglycerides, Trilipix may be utilized. It is often prescribed to help improve the overall lipid profile by lowering total cholesterol and triglycerides while potentially increasing "good" cholesterol (high-density lipoprotein or HDL).

Therapeutic Benefits

The primary goal of Trilipix therapy is to shift the balance of blood lipids toward a healthier range. By addressing lipid imbalances, the medication provides several physiological benefits:

Reduction of Triglycerides: It effectively lowers the concentration of triglycerides, which are the most common type of fat in the body.
Decrease in VLDL Levels: It helps reduce very-low-density lipoprotein (VLDL), which is a precursor to LDL cholesterol.
Increase in HDL Cholesterol: For many patients, Trilipix helps raise levels of high-density lipoprotein, which facilitates the removal of other forms of cholesterol from the bloodstream.

Importance of Comprehensive Management

Trilipix is intended to be one part of a comprehensive treatment plan. The benefits of the medication are most effective when integrated with a heart-healthy lifestyle, which typically includes:

Adherence to a low-fat and low-cholesterol diet.
Regular physical activity and exercise.
Weight management strategies.
Cessation of smoking and moderation of alcohol intake.

Eligibility and Restrictions for Use

Trilipix is officially permitted for use only in adults (18 years of age and older). Eligibility is strictly defined by regulatory documents, which establish several contraindications and population-based restrictions.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults (18 years and older)
Populations for whom use is contraindicated	Severe renal dysfunction (including patients on dialysis); Active liver disease; Pre-existing gallbladder disease; Nursing mothers; Known hypersensitivity to fenofibric acid or fenofibrate.

Eligibility-Related Restrictions

Age-Related Eligibility: The safety and effectiveness of Trilipix in pediatric patients (under 18) have not been established. For geriatric patients, dose selection must be based on an assessment of renal function.
Organ Function Restrictions: Use is avoided in severe renal impairment. In cases of mild to moderate renal impairment, treatment requires special consideration and monitoring.
Reproductive Status: The medicine is contraindicated during lactation. For pregnancy, use is restricted, only permitted if the potential benefit justifies the potential risk to the fetus (Pregnancy Category C).

The regulatory profile sets mandatory boundaries, excluding individuals with specific organ function impairments or certain comorbidities from using this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of fenofibric acid (Trilipix) is structured around managing absorption interference, metabolic inhibition, and additive toxicity risks, as documented in official prescribing information.

Interaction Scope

Classification	Interacting Agents / Rules	Constraint Type
Exposure Modification	Coumarin Anticoagulants (e.g., Warfarin)	Fenofibric acid is documented as a moderate inhibitor of CYP2C9 in in vitro studies, increasing anticoagulant exposure and requiring dosage review and INR monitoring.
Additive Risk	HMG-CoA Reductase Inhibitors (Statins)	Co-administration carries an additive pharmacodynamic risk of myopathy and rhabdomyolysis, leading to a caution classification.
Absorption Timing	Bile Acid Sequestrants	The medicine must be administered at least 1 hour before or 4 to 6 hours after the sequestrant (e.g., Cholestyramine) to prevent interference with its absorption.
Increased Exposure	Gemfibrozil	Co-administration significantly increases fenofibric acid exposure (AUC); this combination is officially not recommended due to heightened risk.
Renal Effect	Cyclosporine	Co-administration may cause a reversible reduction in renal function, which can subsequently increase fenofibric acid exposure, particularly in patients with pre-existing renal impairment.

Connection to the Overall Interaction Profile

The regulatory profile requires specific management for co-administered medicines, notably strict spacing from bile acid sequestrants and caution with CYP2C9 substrates. The interaction structure emphasizes that co-administration with other lipid-modifying agents is subject to official restrictions due to additive toxicity or altered exposure, with the risk being particularly relevant in populations with impaired renal function.

Mechanism of Action

How Trilipix Works: Mechanism of Action

Trilipix (fenofibric acid) works by targeting key regulatory mechanisms of lipid and cholesterol processing. Its primary action is mediated through the activation of the Peroxisome Proliferator-Activated Receptor Alpha ( PPAR-alpha), a specialized nuclear receptor predominantly found in the liver and cells involved in lipid metabolism.

Binding of fenofibric acid to PPAR-alpha alters the transcription (gene expression) of specific genes, initiating signaling sequences that modify downstream molecular steps. This modulation specifically increases the production of the enzyme Lipoprotein Lipase (LPL) and reduces the synthesis of the LPL inhibitor Apolipoprotein C-III (Apo C-III). This mechanistic cascade increases the rate of clearance and catabolism of triglyceride-rich particles, such as VLDL and chylomicrons, from the plasma.

The mechanism further influences lipoprotein composition by increasing the synthesis of Apolipoprotein A-I (Apo A-I), a structural component of High-Density Lipoprotein (HDL). It also promotes the structural shift of Low-Density Lipoprotein (LDL) particles from small, dense forms to larger, less dense forms, modifying feedback regulation within lipid pathways.

Dosage and Administration Information

How to Use Trilipix

This section describes the administration and high-level dosing rules for Trilipix (fenofibric acid delayed-release capsules).

Administration Scope

Property	Official Administration Instruction
Route of Administration	The medicine is approved for oral use only.
Form and Handling	The dose is supplied as a delayed-release capsule that must be swallowed whole; it should not be crushed, broken, dissolved, or chewed.
Dosing Frequency	Trilipix is administered once daily.
Timing Relative to Meals	Doses can be taken without regard to meals (with or without food).

Standard Dosing and Procedural Rules

Treatment with Trilipix requires the initiation and continuation of an appropriate lipid-lowering diet. The specific daily dosage is determined by the patient's condition, with a maximum recommended dose of 135 mg once daily across all approved indications. The standard dose for primary or mixed dyslipidemia is 135 mg once daily, while the initial and maintenance dose range for severe hypertriglyceridemia is between 45 mg to 135 mg once daily.

Dosage adjustments are procedural and based on therapeutic response, with subsequent lipid determinations recommended at 4 to 8 week intervals.

If a dose is missed, patients are advised not to take an extra dose to compensate; therapy should be resumed with the next scheduled dose. For patients with mild to moderate kidney impairment, the labeled initial dosage is 45 mg once daily. If co-administered with a bile acid resin, Trilipix must be taken either 1 hour before or 4 to 6 hours after the resin to prevent reduced absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trilipix

Fenofibric acid (Trilipix) was evaluated in research exploring abnormal blood fat levels through a landscape of research primarily composed of randomized controlled trials (RCTs). These trials are considered a high-level form of evidence and research examined patterns related to key measurements in the blood, known as biomarkers. The findings describe group patterns, not personal outcomes, and are overseen by health authorities like the U.S. Food and Drug Administration (FDA).

Evidence for Managing Severe Hypertriglyceridemia

Research examined the medicine in adult patients with a diagnosis of severe hypertriglyceridemia (TG ge 500 mg/dL) through short-term, randomized controlled trials. The primary outcome measured was the change in the TG biomarker level. The short-term RCTs consistently reported measurements demonstrating patterns of change in the TG biomarker levels during the study period compared to placebo. Research has explored the relationship between managing highly elevated TG levels and the clinical outcome of acute pancreatitis, a condition that may be associated with severe hypertriglyceridemia.

It is not yet clear whether the patterns observed in the TG biomarker were associated with a reduction in the clinical event of acute pancreatitis, particularly for patients with extremely high TG readings (e.g., those over 2,000 mg/dL). Existing studies provide limited insight into this specific clinical outcome, and long-term effects are not fully established beyond the short-term biomarker shifts.

Evidence for Mixed Dyslipidemia and Lipid Marker Shifts

For patients with mixed dyslipidemia, research explored the medicine both as a single therapy (monotherapy) and when used alongside statins (adjunctive therapy). The trials monitored multiple lipid biomarkers, including TG, HDL-C, and LDL-C. Findings indicate that when studies monitored the combination with statins, they focused on achieving changes in a broader range of lipid measurements. While research highlights changes measured in lipid biomarkers, the evidence is limited when assessing the durability of these changes and long-term consequences.

What is Still Uncertain About the Research Evidence

A primary research limitation is that the research has not established a consistent link between the favorable shifts in lipid biomarkers and a statistically definitive reduction in major clinical cardiovascular events for all patient groups. For instance, the findings were mixed concerning the reduction of heart attacks and strokes in the large trials. Evidence is limited regarding the clinical outcome of acute pancreatitis risk reduction. Furthermore, follow-up durations were limited for certain combination uses, meaning that long-term effects are not fully established beyond the observation periods of the published studies.

How should Trilipix be stored and disposed of?

How to Store and Dispose of Trilipix (Fenofibric Acid)

Official regulatory information specifies essential requirements for storing and handling Trilipix, strictly based on product labeling.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, 59 to 86 F (15 to 30 C).
Protection	The product must be protected from moisture.
Container	Keep the medication in the container it came in, with the container tightly closed.
Child Safety	Keep Trilipix and all medicines out of the reach of children.